Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212673 | 0.84 | MAPT (0.61) | DYRK1AMAPTHSD17B10PRKCIFGFR1 | |
| SCHEMBL15823797 | 0.81 | DYRK1A (0.66) | DYRK1APRKCI | |
| SCHEMBL4821253 | 0.78 | DYRK1A (0.53) | DYRK1AMAPTHSD17B10PRKCIALDH1A1 | |
| SCHEMBL19848658 | 0.78 | MAPT (0.44) | DYRK1AMAPTHSD17B10PRKCIDDB1 | |
| SCHEMBL2739230 | 0.78 | DYRK1A (0.53) | DYRK1AMAPTHSD17B10PRKCIFGFR1 | |
| SCHEMBL29522878 | 0.78 | DYRK1A (0.53) | DYRK1AMAPTHSD17B10PRKCIFGFR1 | |
| SCHEMBL30263530 | 0.78 | DYRK1A (0.53) | DYRK1AMAPTHSD17B10PRKCIALDH1A1 | |
| SCHEMBL19911418 | 0.77 | MAPT (0.41) | DYRK1AMAPTHSD17B10PRKCIDDB1 | |
| SCHEMBL7034010 | 0.77 | MAPT (0.57) | MAPTHSD17B10ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL14855712 | 0.76 | DYRK1A (0.51) | DYRK1AMAPTHSD17B10PRKCIALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656602-A2 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | Entegris, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12378463-B2 | Water-based resin with elasticity for applications in cementing and subterranean structures | SAUDI ARABIAN OIL COMPANY (SA) | 2025-08-05 | — | — | US | disclosed |
| EP-4577535-A1 | JAK1/JAK2/TYK2 INHIBITORS FOR TOPICAL TREATMENT OF DERMATOLOGICAL DISEASES | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20240350984-A1 | MEMBRANES FOR REMOVING METALLIC SPECIES FROM AMINES | ENTEGRIS, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12059656-B2 | Membranes for removing metallic species from amines | ENTEGRIS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-11957683-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240093081-A1 | WATER-BASED RESIN WITH ELASTICITY FOR APPLICATIONS IN CEMENTING AND SUBTERRANEAN STRUCTURES | SAUDI ARABIAN OIL COMPANY (SA) | 2024-03-21 | — | — | US | disclosed |
| WO-2024041397-A1 | JAK1/JAK2/TYK2 INHIBITORS FOR TOPICAL TREATMENT OF DERMATOLOGICAL DISEASES | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2024-02-29 | — | — | WO | disclosed |
| EP-4272832-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6043254-A | ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-28 | — | — | US | disclosed |
| WO-1999051590-A1 | SUBSTITUTED INDOLINONES AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-14 | — | — | WO | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | DYRK1A 4124/4885MAPT 4094/4885HSD17B10 1553/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | DYRK1A 4112/4885MAPT 4095/4885HSD17B10 1553/4885 |
| US-11957683-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | DYRK1A 3975/4885MAPT 1168/4885HSD17B10 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.